Eggermont, Alexander M M <br/><br/>
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  07 2019 
 - 148-157 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2019.05.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Melanoma--classification<br/>Middle Aged<br/>Neoplasm Staging--methods<br/>Prognosis<br/>Skin Neoplasms--classification<br/>Treatment Outcome<br/>Melanoma, Cutaneous Malignant